Predictors of receiving a doxycycline postexposure prophylaxis (Doxy-PEP) prescription for the prevention of bacterial sexually transmitted infections (STIs) in a community-based clinic: a case–control study
{"title":"Predictors of receiving a doxycycline postexposure prophylaxis (Doxy-PEP) prescription for the prevention of bacterial sexually transmitted infections (STIs) in a community-based clinic: a case–control study","authors":"Adedotun Ogunbajo, Cody Henry, Alphonso Barney, Tyson Anderson, Joey Brown, DeMarc Hickson","doi":"10.1136/sextrans-2024-056291","DOIUrl":null,"url":null,"abstract":"Studies have found that doxycycline postexposure prophylaxis (Doxy-PEP), when administered within 72 hours of condomless sex, reduces the incidence of syphilis, chlamydia and gonorrhoea among sexual minority men (SMM).1–3 The Centers for Disease Control and Prevention (CDC) recently released clinical guidelines on the administration of Doxy-PEP for sexually transmitted infection (STI) prevention.4 The current study investigated the association between sociodemographic characteristics, sexual risk-taking behaviours, recent STI diagnosis, HIV pre-exposure prophylaxis (PrEP) use and receiving a Doxy-PEP prescription for STI prevention among a sample of racial and sexual minority individuals receiving healthcare services at a community clinic in Washington, DC. We focused on racial and sexual minority populations as these groups are primarily served by the community clinic. We analysed the electronic medical records of clients (n=100) who received services at Us Helping Us, People Into Living, Inc, between May and November 2023. Cases were defined as clients who were prescribed Doxy-PEP and controls were defined as clients who were not prescribed Doxy-PEP. Clients were eligible for Doxy-PEP if they had any reactive STI results in the previous 6 months; the CDC guidelines recommend counselling for sexual minority men (SMM) and …","PeriodicalId":21624,"journal":{"name":"Sexually Transmitted Infections","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexually Transmitted Infections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/sextrans-2024-056291","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Studies have found that doxycycline postexposure prophylaxis (Doxy-PEP), when administered within 72 hours of condomless sex, reduces the incidence of syphilis, chlamydia and gonorrhoea among sexual minority men (SMM).1–3 The Centers for Disease Control and Prevention (CDC) recently released clinical guidelines on the administration of Doxy-PEP for sexually transmitted infection (STI) prevention.4 The current study investigated the association between sociodemographic characteristics, sexual risk-taking behaviours, recent STI diagnosis, HIV pre-exposure prophylaxis (PrEP) use and receiving a Doxy-PEP prescription for STI prevention among a sample of racial and sexual minority individuals receiving healthcare services at a community clinic in Washington, DC. We focused on racial and sexual minority populations as these groups are primarily served by the community clinic. We analysed the electronic medical records of clients (n=100) who received services at Us Helping Us, People Into Living, Inc, between May and November 2023. Cases were defined as clients who were prescribed Doxy-PEP and controls were defined as clients who were not prescribed Doxy-PEP. Clients were eligible for Doxy-PEP if they had any reactive STI results in the previous 6 months; the CDC guidelines recommend counselling for sexual minority men (SMM) and …
期刊介绍:
Sexually Transmitted Infections is the world’s longest running international journal on sexual health. It aims to keep practitioners, trainees and researchers up to date in the prevention, diagnosis and treatment of all STIs and HIV. The journal publishes original research, descriptive epidemiology, evidence-based reviews and comment on the clinical, public health, sociological and laboratory aspects of sexual health from around the world. We also publish educational articles, letters and other material of interest to readers, along with podcasts and other online material. STI provides a high quality editorial service from submission to publication.